Zurcher Kantonalbank Zurich Cantonalbank Acquires 11,459 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 94.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 23,579 shares of the medical technology company’s stock after purchasing an additional 11,459 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Alphatec were worth $356,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Valeo Financial Advisors LLC increased its position in Alphatec by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 19,025 shares of the medical technology company’s stock worth $287,000 after acquiring an additional 900 shares during the period. RiverPark Advisors LLC grew its position in Alphatec by 22.6% in the 4th quarter. RiverPark Advisors LLC now owns 5,033 shares of the medical technology company’s stock worth $76,000 after purchasing an additional 928 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Alphatec by 4.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 22,904 shares of the medical technology company’s stock worth $297,000 after purchasing an additional 1,030 shares during the period. Spouting Rock Asset Management LLC raised its position in shares of Alphatec by 8.8% during the third quarter. Spouting Rock Asset Management LLC now owns 13,592 shares of the medical technology company’s stock valued at $176,000 after buying an additional 1,094 shares during the last quarter. Finally, BluePath Capital Management LLC bought a new stake in shares of Alphatec in the third quarter valued at about $29,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Stock Performance

Shares of NASDAQ:ATEC opened at $13.65 on Friday. The company has a debt-to-equity ratio of 6.54, a current ratio of 2.86 and a quick ratio of 1.99. The business’s fifty day moving average price is $13.39 and its two-hundred day moving average price is $13.53. Alphatec Holdings, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $19.14. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -8.81 and a beta of 1.48.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $131.90 million. During the same quarter last year, the firm posted ($0.33) earnings per share. The business’s revenue was up 30.3% compared to the same quarter last year. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Ratings Changes

ATEC has been the topic of several research reports. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price target on shares of Alphatec in a research note on Wednesday, March 20th. Wells Fargo & Company assumed coverage on Alphatec in a research note on Friday, February 9th. They issued an “overweight” rating and a $26.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Monday, March 4th. Finally, Needham & Company LLC boosted their price target on shares of Alphatec from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and a consensus price target of $23.63.

Insiders Place Their Bets

In other news, EVP David Sponsel sold 2,500 shares of Alphatec stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $16.16, for a total value of $40,400.00. Following the completion of the transaction, the executive vice president now owns 637,418 shares in the company, valued at $10,300,674.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Alphatec news, CFO John Todd Koning sold 121,601 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $13.30, for a total transaction of $1,617,293.30. Following the sale, the chief financial officer now owns 430,856 shares of the company’s stock, valued at approximately $5,730,384.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 2,500 shares of the business’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total transaction of $40,400.00. Following the completion of the transaction, the executive vice president now directly owns 637,418 shares of the company’s stock, valued at $10,300,674.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 285,069 shares of company stock valued at $3,971,495. 29.12% of the stock is currently owned by insiders.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.